Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib.

Anand Ashwin PatelKirk CahillAngella Charnot-KatsikasHongtao LiuSandeep GurbuxaniMichael ThirmanSatyajit KosuriAndrew S ArtzRichard A LarsonWendy StockJeremy SegalOlatoyosi Odenike

Published in: British journal of haematology (2020)

Keyphrases

wild type
low grade
newly diagnosed
high grade